With the Board's unanimous recommendation, two fairness opinions, and support agreements from large holders (directors plus Apeiron, who collectively hold ~15%+), the vote appears likely to pass. The 40% cash premium provides downside protection; the CVR offers upside optionality on pipeline milestones. Traders should monitor for any competing bid emergence given a go-shop provision exists but appears limited, as well as regulatory clearance (HSR, UK CMA, Australia, Germany). If held, consider voting for the deal or selling on the market before the closing to capture the arbitrage spread.
Price Chart
Executive Summary
AtaiBeckley shareholders are asked to vote on the acquisition by Eli Lilly for $6.75 per share in cash plus one CVR per share, which is entitled to up to $2.50 in additional cash upon achievement of specified clinical and regulatory milestones. The upfront cash consideration alone represents an approximately 40% premium over the 30-day VWAP before the deal announcement. The Board unanimously recommends approval, with a special meeting set for September 8, 2026, and closing expected in Q3 2026.
Key Financial Metrics
Key Facts
- Cash consideration of $6.75 per share, plus one CVR per share worth up to an additional $2.50 in cash upon achievement of clinical and regulatory milestones.
- Upfront cash consideration represents approximately 40% premium to the 30-day VWAP ended July 15, 2026.
- Total upfront deal value approximately $2.8 billion in cash.
- Board unanimously recommends adoption of the merger agreement.
- Special meeting scheduled for September 8, 2026; record date August 7, 2026.
- Requires affirmative vote of holders of a majority of outstanding shares.
- Directors and executive officers, along with Apeiron Investment Group Ltd., have entered into voting and support agreements to vote in favor.
- Centerview Partners and Moelis & Company each rendered fairness opinions that the merger consideration is fair from a financial point of view.
- Appraisal rights available under Delaware law for shareholders who do not vote in favor.
Financial Impact
Total upfront cash consideration of approximately $2.8 billion based on 370,864,669 shares outstanding at $6.75 per share, plus up to $927 million additional potential milestone payments via CVRs ($2.50 per share on the same share count).
Risk Factors
- Regulatory risks: deal requires antitrust clearance in the U.S. (HSR Act), Germany (obtained July 30, 2026), Australia, and the UK; any challenge could delay or prevent closing.
- Execution risk: failure to obtain stockholder vote (though likely given support agreements from ~15.2% holder block).
- Pipeline risk: CVR milestones depend on clinical and regulatory success of VLS-01 and BPL-003; no guarantee of payment.
- Market/counterparty risk: if Lilly terminates or a superior proposal emerges, AtaiBeckley owes a termination fee of $104.3 million.
Market Snapshot
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001140361-26-031922 |
| Document: ny20078129x2_defm14a.htm | 0001140361-26-031922 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 25-NSE | $7.30 awaiting T+20 | awaiting T+20 | — | — |
Aug 10, 2026 7w ago | DEFM14A | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Aug 9, 2026 7w ago | Institutional Cluster | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Jul 16, 2026 11w ago | DEFA14A / 8-K | $7.15 $7.25 | ▲ +1.40% | ▼ −2.22% | — |
Jul 7, 2026 12w ago | 144 | $5.17 $7.22 | ▲ +39.65% | ▲ +36.38% | — |
Jul 6, 2026 12w ago | Press Release | $4.96 $7.18 | ▲ +44.76% | ▲ +45.32% | — |
Jun 26, 2026 14w ago | 144 | $5.36 $7.18 | ▲ +33.96% | ▲ +34.23% | — |
Jun 25, 2026 14w ago | 144 | $5.29 $7.17 | ▲ +35.54% | ▲ +34.28% | — |
Jun 3, 2026 17w ago | 8-K | $4.53 $5.19 | ▲ +14.57% | ▲ +15.57% | — |
May 12, 2026 20w ago | Press Release | $4.15 $3.78 | ▼ −8.92% | ▼ −7.19% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access